Press Releases
Specifica Announces Antibody Discovery Platform Transfer to Bayer
Company’s Generation 3 Antibody Platform Delivers High-Affinity, Drug-Like Antibody Candidates Well Designed to Facilitate the Development of High-Quality Therapeutics Santa Fe, New Mexico, May 12, 2020 — Specifica, a leading…
May 12, 2020
News
Specifica CSO, Andrew Bradbury, participates in this Miltenyi webcast on the importance of recombinant antibodies.
Specifica CSO, Andrew Bradbury, participates in this Miltenyi webcast on the importance of recombinant antibodies.Read the full article HERE.
June 03, 2018
